Teva Pharmaceutical adds David Brailer to board of directors

Teva Pharmaceutical Industries Ltd disclosed in an 8-K filing that its Board of Directors elected Dr. David J. Brailer to serve as a member of the Board at a meeting on October 27, 2026, effective November 3, 2026, until Teva's 2027 annual meeting of shareholders.¹ The filing noted that the Board determined Dr. Brailer qualifies as an independent director under New York Stock Exchange listing rules, and he is expected to serve on the Human Resources and Compensation and Compliance Committees.¹

According to the filing, Dr. Brailer currently leads medem.ai, a health-tech company, as its chairman and chief executive since 2024, and has run Health Evolution as founder and executive chairman since 2010, along with Health Evolution Partners, where he has been founder and managing partner since 2007. The filing also states that from 2022 to 2026, Dr. Brailer served as Chief Health Officer of The Cigna Group and, from 2024 to 2026, also as its Chief Transformation Officer.¹ He has additionally held the role of vice chairman at the Duke Margolis Health Policy Institute since 2021, per the filing. Teva noted Dr. Brailer previously served on the boards of directors of Prolacta Bioscience, Inc. from 2012 to 2023, and Walgreens Boots Alliance, Inc., from 2012 to 2021.¹

His academic credentials include a doctorate in management science and applied economics earned at the Wharton School of the University of Pennsylvania, along with a medical degree and a bachelor's degree from West Virginia University, the filing said.

Teva stated that Dr. Brailer will receive the same compensation as Teva's other non-executive directors, as described in the company's definitive proxy statement filed with the SEC on March 31, 2026.¹ The filing also confirmed that there are no arrangements between Dr. Brailer and any other persons related to his election, no material interest in related party transactions, and no family relationships with any Teva director or executive officer.¹